Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer.
Lin Zhang,Stefano Volinia,Tomas Bonome,George Adrian Calin,Joel Greshock,Nuo Yang,Chang-Gong Liu,Antonis Giannakakis,Pangiotis Alexiou,Kosei Hasegawa,Cameron N Johnstone,Molly S Megraw,Sarah Adams,Heini Lassus,Jia Huang,Sippy Kaur,Shun Liang,Praveen Sethupathy,Arto Leminen,Victor A Simossis,Raphael Sandaltzopoulos,Yoshio Naomoto,Dionyssios Katsaros,Phyllis A Gimotty,Angela DeMichele,Qihong Huang,Ralf Bützow,Anil K Rustgi,Barbara L Weber,Michael J Birrer,Artemis G Hatzigeorgiou,Carlo M Croce,George Coukos
DOI: https://doi.org/10.1073/pnas.0801615105
2008-01-01
Abstract:MicroRNAs (miRNAs) are an abundant class of small noncoding RNAs that function as negative gene regulators. miRNA deregulation is involved in the initiation and progression of human cancer; however, the underlying mechanism and its contributions to genome-wide transcriptional changes in cancer are still largely unknown. We studied miRNA deregulation in human epithelia[ ovarian cancer by integrative genomic approach, including miRNA microarray (n = 106), array-based comparative genomic hybridization (n = 109), cDNA microarray (n = 76), and tissue array (n = 504). miRNA expression is markedly down-regulated in malignant transformation and tumor progression. Genomic copy number loss and epigenetic silencing, respectively, may account for the down-regulation of approximate to 15% and at least approximate to 36% of miRNAs in advanced ovarian tumors and miRNA down-regulation contributes to a genome-wide transcriptional deregulation. Last, eight miRNAs located in the chromosome 14 miRNA cluster (Dlk1-Gtl2 domain) were identified as potential tumor suppressor genes. Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer.